Zugriffszahlen seit März 2016. Zugriffszahlen aus dem Vorgängersystem werden nicht mitberücksichtigt.

Total Visits

Views
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study89

Total Visits Per Month

July 2021August 2021September 2021October 2021November 2021December 2021January 2022
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study6430200

Top country views

Views

Top cities views

Views